← Back to Screener
Vor Biopharma Inc. Common Stock (VOR)
Price$14.97
Favorite Metrics
Price vs S&P 500 (26W)-57.28%
Price vs S&P 500 (4W)14.18%
Market Capitalization$762.02M
All Metrics
Book Value / Share (Quarterly)$10.58
P/TBV (Annual)0.50x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.71
Price vs S&P 500 (YTD)16.62%
EPS (TTM)$-293.19
10-Day Avg Trading Volume1.38M
EPS Excl Extra (TTM)$-293.19
EPS (Annual)$-70.50
ROI (Annual)-120.95%
Cash / Share (Quarterly)$11.76
ROA (Last FY)-149.96%
EBITD / Share (TTM)$-70.81
ROE (5Y Avg)-71.50%
Cash Flow / Share (Annual)$-3.71
P/B Ratio11.53x
P/B Ratio (Quarterly)1.36x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-24.81x
ROA (TTM)-291.50%
EPS Incl Extra (Annual)$-70.50
Current Ratio (Annual)18.20x
Quick Ratio (Quarterly)18.15x
3-Month Avg Trading Volume1.60M
52-Week Price Return12.88%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.58
52-Week High$65.80
EPS Excl Extra (Annual)$-70.50
CapEx CAGR (5Y)-25.72%
26-Week Price Return-53.29%
Quick Ratio (Annual)18.15x
13-Week Price Return10.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)18.20x
Enterprise Value$365.535
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.76
3-Month Return Std Dev91.88%
Net Income / Employee (TTM)$-4
ROE (Last FY)-120.95%
EPS Basic Excl Extra (Annual)$-70.50
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-293.19
ROI (TTM)-142.13%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.80
Price vs S&P 500 (52W)-16.95%
Year-to-Date Return19.27%
5-Day Price Return0.00%
EPS Normalized (Annual)$-70.50
ROA (5Y Avg)-70.09%
Month-to-Date Return-12.56%
Cash Flow / Share (TTM)$-1.82
EBITD / Share (Annual)$-70.80
ROI (5Y Avg)-71.50%
EPS Basic Excl Extra (TTM)$-293.19
P/TBV (Quarterly)0.71x
P/B Ratio (Annual)0.79x
Book Value / Share (Annual)$15.49
Price vs S&P 500 (13W)9.56%
Beta1.79x
Revenue / Share (TTM)$0.00
ROE (TTM)-142.13%
52-Week Low$2.62
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.18
4.18
4.23
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VORVor Biopharma Inc. Common Stock | — | — | — | — | $14.97 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Vor Biopharma is a clinical-stage cell therapy company developing engineered cell therapies for hematological malignancies using proprietary patient engineering technology. The company's lead programs include VCAR33 and Tremcel, with additional candidates targeting CD123, CLL1, and EMR2 markers for blood cancers and myelodysplastic syndrome.